Altimmune Q3 2023 Earnings Report $6.43 -0.20 (-3.02%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Altimmune EPS ResultsActual EPS-$0.39Consensus EPS -$0.40Beat/MissBeat by +$0.01One Year Ago EPSN/AAltimmune Revenue ResultsActual Revenue$0.36 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAltimmune Announcement DetailsQuarterQ3 2023Date11/7/2023TimeN/AConference Call ResourcesPress ReleaseALT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Altimmune Earnings HeadlinesAltimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025February 20 at 7:30 AM | globenewswire.comAltimmune put volume heavy and directionally bearishFebruary 20 at 12:23 AM | markets.businessinsider.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. February 22, 2025 | Crypto 101 Media (Ad)Altimmune, Inc. (NASDAQ:ALT) Sees Large Decline in Short InterestFebruary 19 at 2:36 AM | americanbankingnews.comAltimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASHFebruary 18, 2025 | seekingalpha.comH.C. Wainwright maintains Buy on Altimmune stock, $12 targetFebruary 6, 2025 | msn.comSee More Altimmune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Altimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Altimmune and other key companies, straight to your email. Email Address About AltimmuneAltimmune (NASDAQ:ALT), a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.View Altimmune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
